BioNTech and Pfizer say their COVID-19 vaccine candidate is 90% effective, a much higher benchmark than anticipated – MarketWatch
BioNTech and Pfizer Inc. s COVID-19 vaccine candidate is the first to demonstrate it can protect most people from contracting symptomatic infections with the virus in a Phase 3 clinical trial an announcement that puts the companies in the lead to bring to market the first COVID-19 vaccine in the U.S.
Shares of BioNTech BNTX,
+13.41% gained 7.7% in trading on Monday, while Pfizer s PFE,+8.75% stock is up 7.6%.The vaccine announcement, in addition to the expected confirmation over the weekend that Joe Biden won the U.S. presidential election, sent U.S. stock-index futures soaring on Monday before the market opened.
I wish I’d known this was coming.